NEW YORK (GenomeWeb) – Quidel reported after the close of the market on Thursday that its first quarter revenues improved 31 percent year over year as new product revenues more than doubled and infectious disease test revenues grew sharply. 

The San Diego-based firm said that revenues for the three months ended March 31 increased to $61.3 million compared to $46.7 million in Q1 2014, nudging past the average analysts' estimate of $61.2 million. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.